263 related articles for article (PubMed ID: 34274878)
1. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
2. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
3. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
8. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
9. Circulating Biomarkers for Cardiotoxicity Risk Prediction.
Gong FF; Cascino GJ; Murtagh G; Akhter N
Curr Treat Options Oncol; 2021 Apr; 22(6):46. PubMed ID: 33866434
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
Konala VM; Adapa S; Aronow WS
Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
[TBL] [Abstract][Full Text] [Related]
11. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Toxicities of CAR T-cell Therapy.
Patel NP; Doukas PG; Gordon LI; Akhter N
Curr Oncol Rep; 2021 May; 23(7):78. PubMed ID: 33937946
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
14. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
[TBL] [Abstract][Full Text] [Related]
15. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
[TBL] [Abstract][Full Text] [Related]
16. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
17. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
Achim A; Liblik K; Gevaert S
Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
